The approved patent protects the composition and method behind the company’s oral probiotic product formulation Kibow Biotics, which may significantly reduce concentrations of several nitrogenous waste metabolites that accumulate in renal deficiency.
Natarajan Ranganathan, vice president of R&D and interim CEO, Kibow, said: “The rapidly expanding intellectual property portfolio for our unique ‘enteric dialysis’ platform technology has added immense potential to our company products for kidney failure applications worldwide.”